Search Results for 'Corporal'

When the English forces regained control of Castlebar after the departure of General Humbert, the greater part of the County Prison on the Green was taken from the control of Governor Henry Moran and set aside for military purposes. Provost Martial William Clavroge assumed responsibility for the military section and military prisoners. Apart from a few common criminals, the prison population of 190 comprised captured Irish rebels, deserters from the British military and militias, and political prisoners such as John Moore.

“There is always a way to resist.”

In November 1824, the Church Wardens of Castlebar sought proposals from contractors to build a new church. Plans were displayed at the house of the Revd. William Smith.

Neale native Oliver Browne is to be honoured by a leading Irish community group in New Jersey, on the night before Mayo play New York in Gaelic Park, New York.

The US navy is to name a destroyer after Ballyhaunis native Patrick Gallagher. The USS Gallagher, as it will be called, will be built in Maine.

US pharmaceutical Company, Aerie Pharmaceuticals, Inc. is to establish its first manufacturing plant in Athlone. Aerie is a clinical stage pharmaceutical company focused on the discovery, development and commercialisation of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

Aerie Pharmaceuticals establishes state of the art manufacturing facility in Athlone

US Pharmaceutical Company, Aerie Pharmaceuticals, is to establish its first manufacturing plant in Athlone’s Technology & Business Park with an initial investment of €55m. Some 80 jobs will be created at the plant.

US pharmaceutical Company, Aerie Pharmaceuticals, Inc. is to establish its first manufacturing plant in Athlone’s Technology & Business Park. Headquartered in California, with locations in New Jersey, North Carolina, Aerie has also established an Irish entity in Dublin, Aerie Pharmaceuticals Ireland Ltd. Aerie is a clinical stage pharmaceutical company focused on the discovery, development and commercialisation of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.